Vibrant Therapeutics: $61 Million Closed And Han Lee Named As Co-CEO
By Amit Chowdhry ● Yesterday at 11:38 AM
Vibrant Therapeutics, a clinical-stage biotech developing “logic-gated” therapeutics designed to activate selectively in diseased tissue, announced it has raised $61 million in new financing and appointed Han Lee, Ph.D. as co-chief executive officer as the company prepares to broaden global development of its lead solid tumor program. The round brought in new investors, Pfizer Ventures and Apricot Capital, and included participation from Bayland Capital, HSG, Northern Light Venture Capital, and First Principle Venture Limited, according to the company. With the latest proceeds, Vibrant said its total capital raised now stands at $100 million.